KALV Quote, Financials, Valuation and Earnings

Perspective Therapeutics, Inc. has a net margin of -361.39% compared to KalVista Pharmaceuticals, Inc.'s net margin of -12425.36%. KalVista Pharmaceuticals, Inc.'s return on equity of -243.25% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

KalVista Pharmaceuticals, Inc. has a consensus price target of $31.00, signalling upside risk potential of 96.33%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 349.19%. Given that Perspective Therapeutics, Inc. has higher upside potential than KalVista Pharmaceuticals, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than KalVista Pharmaceuticals, Inc..

KalVista Pharmaceuticals, Inc. has a beta of -0.135, which suggesting that the stock is 113.476% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.

KalVista Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. KalVista Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

KalVista Pharmaceuticals, Inc. quarterly revenues are $13.7M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. KalVista Pharmaceuticals, Inc.'s net income of -$49.5M is lower than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, KalVista Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for KalVista Pharmaceuticals, Inc. is 54.78x versus 190.87x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Electromed, Inc. has a net margin of -361.39% compared to KalVista Pharmaceuticals, Inc.'s net margin of 12.65%. KalVista Pharmaceuticals, Inc.'s return on equity of -243.25% beat Electromed, Inc.'s return on equity of 18.89%.

KalVista Pharmaceuticals, Inc. has a consensus price target of $31.00, signalling upside risk potential of 96.33%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 25.31%. Given that KalVista Pharmaceuticals, Inc. has higher upside potential than Electromed, Inc., analysts believe KalVista Pharmaceuticals, Inc. is more attractive than Electromed, Inc..

KalVista Pharmaceuticals, Inc. has a beta of -0.135, which suggesting that the stock is 113.476% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.

KalVista Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. KalVista Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

KalVista Pharmaceuticals, Inc. quarterly revenues are $13.7M, which are smaller than Electromed, Inc. quarterly revenues of $16.9M. KalVista Pharmaceuticals, Inc.'s net income of -$49.5M is lower than Electromed, Inc.'s net income of $2.1M. Notably, KalVista Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 30.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for KalVista Pharmaceuticals, Inc. is 54.78x versus 3.83x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Silvergate Capital has a net margin of -361.39% compared to KalVista Pharmaceuticals, Inc.'s net margin of --. KalVista Pharmaceuticals, Inc.'s return on equity of -243.25% beat Silvergate Capital's return on equity of --.

KalVista Pharmaceuticals, Inc. has a consensus price target of $31.00, signalling upside risk potential of 96.33%. On the other hand Silvergate Capital has an analysts' consensus of -- which suggests that it could fall by --. Given that KalVista Pharmaceuticals, Inc. has higher upside potential than Silvergate Capital, analysts believe KalVista Pharmaceuticals, Inc. is more attractive than Silvergate Capital.

KalVista Pharmaceuticals, Inc. has a beta of -0.135, which suggesting that the stock is 113.476% less volatile than S&P 500. In comparison Silvergate Capital has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

KalVista Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Silvergate Capital offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. KalVista Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Silvergate Capital pays out -- of its earnings as a dividend.

KalVista Pharmaceuticals, Inc. quarterly revenues are $13.7M, which are larger than Silvergate Capital quarterly revenues of --. KalVista Pharmaceuticals, Inc.'s net income of -$49.5M is higher than Silvergate Capital's net income of --. Notably, KalVista Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Silvergate Capital's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for KalVista Pharmaceuticals, Inc. is 54.78x versus -- for Silvergate Capital. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -361.39% compared to KalVista Pharmaceuticals, Inc.'s net margin of 3.93%. KalVista Pharmaceuticals, Inc.'s return on equity of -243.25% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

KalVista Pharmaceuticals, Inc. has a consensus price target of $31.00, signalling upside risk potential of 96.33%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 92.8%. Given that KalVista Pharmaceuticals, Inc. has higher upside potential than Xtant Medical Holdings, Inc., analysts believe KalVista Pharmaceuticals, Inc. is more attractive than Xtant Medical Holdings, Inc..

KalVista Pharmaceuticals, Inc. has a beta of -0.135, which suggesting that the stock is 113.476% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

KalVista Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. KalVista Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

KalVista Pharmaceuticals, Inc. quarterly revenues are $13.7M, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. KalVista Pharmaceuticals, Inc.'s net income of -$49.5M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, KalVista Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 76.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for KalVista Pharmaceuticals, Inc. is 54.78x versus 0.85x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.